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Abstract 
In view of the close similarity between bovine leukemia virus (BLV) and human T-cell leukemia virus type I (HTLV-I) we investigated the possibility 
of developing specific inhibitors of the proteases of these retroviruses using the purified enzyme from BLV. We tested the ability of this protease 
to specifically cleave various short oligopeptide substrates containing cleavage sites of BLV and HTLV-I proteases, as well as a recombinant BLV 
Gag precursor. The best substrate, a synthetic decapeptide b ating the natural cleavage site between the matrix and the capsid proteins of BLV Gag 
precursor polyprotein, was used to develop an inhibition assay. We determined the relative inhibitory effect of synthetic Gag precursor-like peptides 
in which the cleavable site was replaced by a non-hydrolyzable moiety. The encouraging inhibitory effect of these compounds indicates that potent 
non-peptidic nhibitors for retroviral proteases are not unattainable. 
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1. Introduction 
Human T-cell leukemia virus type I (HTLV-I) and 
bovine leukemia virus (BLV) are closely related retro- 
viruses [1,2] that are the etiological agents of adult T-cell 
leukemia and enzootic bovine lymphosarcoma, respec- 
tively [3-7]. In common with the virus itself, the protease 
(PR) of BLV strongly resembles the corresponding 
HTLV-I enzyme [8,9]. Both PRs are responsible for 
processing both the initial translation products (precur- 
sors Gag-Pro-Pol, Gag-Pro and Gag) into functional 
enzymes (protease, reverse transcriptase and integrase) 
and the mature structural proteins of the matrix, capsid 
and nucleocapsid (MA, CA, NC) [10-13], which are re- 
quired for infectivity [14]. PR is thus a prime target for 
potential therapeutic agents in the fight against the dis- 
eases induced by these retroviruses. Because native BLV 
PR is easier to obtain to a high degree of purity than 
HTLV-I PR, the former was employed in the experi- 
ments reported here. In order to develop suitable inhib- 
itors, we checked that BLV PR cleaved peptides at the 
same sites as those cleaved by the HTLV-I enzyme. We 
therefore developed an in vitro inhibition assay using the 
substrate with the highest sensitivity that was also the 
most readily analyzed. Using this test, we examined the 
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potential inhibitory activity of a variety of compounds. 
BLV and HTLV-I PRs have been isolated by several 
groups [13,15-19], although the efficiency of specific in- 
hibitors has yet to be reported. 
2. Materials and methods 
2.1. Source of viral BLV PR 
BLV PR was purified from virion particles under non-denaturating 
conditions. In brief, pure and active PR was obtained by cation-ex- 
change chromatography followed by hydrophobic hromatography. 
PR in this preparation was found to be most active at pH 6, 40°C and 
high salt concentration (1-2 M NaCl or ammonium sulfate) using a 
synthetic peptide as substrate [20]. 
2.2. Assay for protease activity with synthetic peptides 
All the peptides used in the experiments were synthesized by the 
Merrifield solid-phase method [21]. Proteolytic reactions were carried 
out in 100 #l of 0.1 M sodium citrate, pH 6, 1 M NaCI containing 10 -9 
mol of peptide. The reaction was initiated by adding 10 -11 mol of PR, 
and the reaction mixture was incubated at 37°C for 30 min. Reactions 
were stopped by immersion in a boiling water bath for 5 rain, and the 
reaction products were analyzed by RP-HPLC. 
2.3. Assay for protease activity with Gag precursor 
The BLV recombinant Gag precursor was expressed in a vaccinia 
virus production system (IFFA Laboratories, Rh6ne M6rieux, Lyon, 
France) and purified by affinity chromatography using a rabbit anti- 
p24 polyclonal antibody. The reactions were carried out in 100 gl of 
0.1 M sodium citrate, pH 6, 0.1 M NaCl at 40°C for 30 min with 10 -9 
mol of Gag precursor and 10-11 mol of PR. Immunoblot analysis of Gag 
cleavage reaction involved transfer to nitrocellulose, development with 
murine anti-p24 monoclonal antibody as the primary probe and alka- 
line phosphatase-conjugated Ig (H and L) mouse antibodies as the 
detection probe. 
2.4. Inhibition assay 
The proteolytic reactions were carried out in 10/zl of 0.1 M sodium 
citrate, pH 6, 1 M NaC1 containing 10 -1° mol of the 12SI-labeled 9003 
substrate, including various concentrations of inhibitor. The reaction 
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was initiated by adding 10 -12 mol of PR, and the reaction mixture was 
incubated at 37°C for 30 rain. Reactions were stopped by immersion 
in a boiling water bath for 5 min, and the reactions products were 
analyzed by thin layer electrophoresis on cellulose plates. The plates 
were dried and autoradiographed. Radioactivity was counted from 
spots removed from the autoradiograms and the reaction efficiency 
determined [20]. 
3. Results and discussion 
Under the optimum activity conditions of BLV PR 
(see section 2), we tested peptidic substrates harboring 
the recognition cleavage sites of the BLV and HTLV-I 
PRs. 
Peptide 9003 (Table 1) contains the cleavage site be- 
tween the MA and CA domains of the BLV Gag pol- 
yprotein. As previously described, this peptide was 
cleaved at the expected site by PR [20], and was used as 
a positive control. 
Peptide 9214 harbored the cleavage site of the N-ter- 
minal end of BLV PR. It contained aminobutyric acid 
instead of the cystein residue to prevent possible disulfide 
bonding between identical peptides. One of the expected 
hydrolyzed products was peptide 9215. This latter pep- 
tide had a retention time (Rr) of 12.4 min on a RP-HPLC 
column (data not shown). Under the same conditions, 
native peptide 9214 had a RT of 21.2 rain, while the same 
peptide incubated with PR gave, in addition to 9214 itself 
(Rr - 21.2 min), an additional peak (Rr = 12.4 min) cor- 
responding to the hydrolyzed byproduct (Fig. 1A). 
We also checked whether BLV PR processed its natu- 
ral Gag precursor substrate correctly. The proteolytic 
reaction was carried as detailed in section 2. After 30 min 
incubation, three major bands (39, 36 and 24 kDa) were 
detected on SDS-PAGE, corresponding to the predicted 
molecular weights of the CA linked to the NC, the MA 
linked to the CA, and the CA, respectively (Fig. 2). These 
results suggested that BLV PR cleaves at the predicted 
site of the BLV Gag precursor. 
Peptides 9306 and 8812 harbor the cleavage site be- 
tween the MA and CA domains of the HTLV-I Gag 
precursor. The reaction was carried out and analyzed as 
described in section 2. Peptide 9306 was cleaved at the 
expected site by PR, generating a peptide corresponding 
to the hydrolyzed by-product 9307 (Fig. 1B). We also 
checked whether the BLV PR could cleave a shorter 
peptide than peptide 9306. We tested activity on peptide 
8812 using peptide 8814 as the control. We found that 
8812 was uncleaved even with longer incubation times (3, 
6, 12 and 24 h) and/or higher concentrations ofPR (data 
not shown). It is noteworthy that peptide 9306 was 
cleaved whereas 8812 was not. This is indicative of an 
influence on site recognition by PR of the length of the 
peptide and the surrounding three-dimensional struc- 
ture. 
With respect to the C-terminal end of the HTLV-I PR, 
the dipeptide L-147/P-148 has been proposed as a cleav- 
age site by Oroszlan and Luftig [22]. A fusion protein 
with an HTLV-I PR containing only 115 amino acids 
(P-33 to L-147) has also been shown to be active on 
peptide 9003 (Llido et al., manuscript in preparation). 
We thus tested the ability of the BLV PR to cleave the 
dipeptide L-147/P-148. For this, we assayed peptides 
8911 and 9101 using the expected hydrolysis product 
Table 1 
Activity of BLV protease towards the different substrates 
Peptide number Amino acid sequence Represented cleavage site Relative activity 
BLV 
9003 Y-D-P-P-A-I-L,[,P-I-I MA/CA 1.0 
9002 Y-D-P-P-A-I-L - 
9214 A-E-L-E-aBu-LSL-S-I-P-L-A NTermPR 0.7 
9215 L-S-I-P-L-A - 
HTLV-I 
9306 A-P-Q-V-LSP-V-M-H-P MA/CA 2 
9307 P-V-M-H-P - 
8812 Ac P-Q-V-LSP-V-M MA/CA 0 
8814 Ac P-Q-V-L - 
8911 G-V-L-Y-LSP-E-A-K-R CTermPR(1) 0 
9101 G-V-L-Y-LSP-E-A CTermPR( 1 ) 0 
9000 G-V-L-Y-L - 
9312 K-G-P-P-V-I-LSP-I-Q-D-P CTermPR(2) 0.9 
9313 P-I-Q-D-P - 
$ represents he cleavage site. aBu represents aminobutyric a id. The 9002, 9215, 9307, 8814, 9000 and 9313 peptides (non-cleavable controls) represent 
the expected products on proteolysis of peptides 9003, 9214, 9306, 8812, 891 l, 9101 and 9313, respectively. 
CTermPR(1) and CTermPR(2) represent the cleavage site of the C-terminal end of the HTLV-I PR which has been proposed by Oroszlan and Luftig 
[22] and by Kobayashi et al. [17], respectively. 
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Fig. 1. Activity of BLV PR against peptides 9214 (A), 9306 (B) and 9312 
(C). The peptidic reaction products from the activity test were loaded 
onto a RP-HPLC VSC4-25FC4 column (5/~m, 250 x 4.6 mm; Inter- 
chim) and eluted in 0.1% TFA at a constant flow rate of 1 ml/min with 
a 30 min linear gradient of acetonitrile at 20"C. The diagonal ine 
represents progress of the gradient. (A) Peptide 9214 (1) is cleaved by 
BLV PR generating the peptide (2) corresponding to the hydrolyzed 
byproduct 9215. The peptide corresponding to the sequence A-E-L-E- 
aBu-L was eluted at the beginning of the gradient. (B) Peptide 9306 (1) 
is cleaved by BLV PR, generating two peptides corresponding to the 
hydrolyzed by-product 9307 (2) and to the peptide A-P-Q-V-L (3). (C) 
Peptide 9312 (1) is cleaved by BLV PR, generating two peptides corre- 
sponding to the hydrolyzed by-product 9313 (2) and to the peptide 
K-G-P-P-V-I-L (3). 
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Fig. 2. Immunoblot analysis of cleavage products of BLV PR on BLV 
recombinant Gag precursor. Lanes 1-7 correspond to incubation times 
of 0, 30 min, 1, 2, 3, 6 and 24 h, respectively. Lanes 8 and 9 correspond 
to the Gag precursor incubated for 24 h without PR and to 2/tg of BLV 
proteins, respectively. 
9000 as a control (see section 2). The 8911 and 9101 
peptides remained uncleaved even with longer incuba- 
tion times (3, 6, 12 and 24 h) and/or higher PR concentra- 
tions (data not shown). In contrast, peptide 9312, con- 
taining the dipeptide L-157/P-158, proposed by 
Kobayashi et al. [17] as the cleavage site of the HTLV-I 
PR C-terminal end, gave, in addition to 9312 itself, two 
additional peaks corresponding tothe hydrolyzed bypro- 
duct 9313 and to the sequence K-G-P-P-V-I-L, respec- 
tively (Fig. 1C). These results indicated that this site is 
recognized, and that the dipeptide L-157/P-158 is proba- 
bly the cleavage site of the HTLV-I PR C-terminal end. 
Taken together the results reported above indicated 
that 9003 and the BLV recombinant Gag precursor were 
the best BLV substrates for the development of an inhi- 
bition assay. However, as the proteolysis of substrate 
9003 could be more readily analyzed than that of the 
BLV recombinant Gag precursor substrate, the former 
was employed to examine the inhibitory effect of test 
compounds. Pepstatin A (Sienna) was used as the refer- 
ence agent for qualitative and quantitative inhibition. 
Under our experimental conditions, the concentration 
for 50% inhibition (ICs0) of BLV PR by pepstatin A was 
in the range of 3-5 x 10 -4 M. 
It has been demonstrated that the site located at the 
junction of the MA and CA fragments is efficiently 
cleaved by PR [15,18]. We therefore decided to synthe- 
size a primary inhibitor containing the MA and CA envi- 
ronment for use as a standard. Since peptide 9003 was 
found to be the best substrate for BLV PR, we synthe- 
sized a peptide (9004) in which the two amino acids of 
the cleavable site were replaced by the non-hydrolyzable 
A. M~nard et al./FEBS Letters 346 (1994) 268-272 
Table 2 
Inhibitory activity of peptides against BLV protease 
271 
Peptide number Sequence Cleavage site ICso(M) 
Pepstatin A 3-5 × 10 -4 
9004 Y-D-P-P-A-I-STA-I-I BLV MAJCA 5.0 × 10 -7 
8901 Ac P-Q-V-L-r-P-V-M HTLV-I MAJCA 1.0 x 10 -5 
8903 Ac P-Q-V-L-PIP-V-M HTLV-I MAJCA 1.5 x 10 -5 
8904 Ac P-Q-V-L-AZE-V-M HTLV-I MA/CA 2.5 x l0 -4 
8813 P-Q-V-STA-A-L HTLV-I MA/CA 1.0 x 10 -4 
STA, ', PIP, and AZE represent the statin residue, the reduced bond, the pipecolic acid and the azetidine residues, respectively. 
statin residue (Table 2). The IC50 of BLV PR by 9004 was 
around 5.0 x 10 -7 M. 
As BL¥ PR has been found to correctly process an 
HTLV-I recombinant Gag precursor [20] and peptide 
9306, a HTLV-I peptide substrate, we also tested the 
activity of potential inhibitors of HTLV-I PR based on 
models of the enzyme structure. Although the 8812 pep- 
tide was not cleaved by BLV PR, the models indicated 
that molecules derived from its 3D structure should in- 
hibit BLV and HTLV-I PRs (unpublished results). Com- 
pounds 8901, 8903, 8904 and 8813 were thus synthesized 
as potential inhibitors [24]. These molecules were con- 
structed from the 111-117 sequence in which the cleav- 
age site was replaced by a non-hydrolyzable moiety 
(Table 2). Best inhibition was obtained with compounds 
8903, which contained the pipecolic acid residue (IC50 
15/aM), and 8901 containing the reduced bond (IC50 
10 /aM), whereas compounds bearing the azetidine 
(8904) or the statin residues (8813) displayed almost no 
inhibitory effect against BLV PR (IC50 of around 
2.5 x 10 -4 M and 1.0 × 10 -4 M,  respectively). 
Leupeptin, soybean trypsin inhibitor, chymostatin, 
antipapain and pepstatin A have all been tested on BLV 
and HTLV-I PRs [25], but only pepstatin A was found 
to produce a significant inhibition. Our results with pep- 
statin A are in good agreement with these findings. Since 
this compound cannot be employed in the treatment of 
leukemia, more specific inhibitors are required. On the 
basis of the results on the various substrates, we tested 
several modified substrates as inhibitors. The greatest 
inhibition of the BLV PR was observed with peptide 
9004 (100-fold more active than pepstatin A), which is 
derived from the BLV PR cleavage site. Most of the 
inhibitors bearing a modified HTLV-I PR cleavage site 
were less efficient than compound 9004, but were all 
significantly more efficient han pepstatin A. 
As peptidic inhibitors are susceptible to proteolytic 
degradation i vivo, they are likely to be ineffective ther- 
apeutically. Nevertheless the results reported here indi- 
cate that more specific, non-peptidic inhibitors of retro- 
viral proteases could be developed. 
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